Venus Concept Inc. (NASDAQ:VERO) Short Interest Update

Venus Concept Inc. (NASDAQ:VERO) saw a large decrease in short interest during the month of August. As of August 31st, there was short interest totalling 13,100 shares, a decrease of 85.7% from the August 15th total of 91,500 shares. Based on an average trading volume of 319,700 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.4% of the company’s shares are short sold.

Venus Concept Trading Down 2.7 %

Shares of VERO stock traded down $0.02 on Friday, reaching $0.55. The company had a trading volume of 13,699 shares, compared to its average volume of 768,903. The company has a current ratio of 1.99, a quick ratio of 1.30 and a debt-to-equity ratio of 9.72. The stock has a market cap of $3.96 million, a PE ratio of -0.08 and a beta of 0.51. The company has a 50-day moving average of $0.60 and a 200-day moving average of $0.68. Venus Concept has a 12 month low of $0.46 and a 12 month high of $2.44.

Venus Concept (NASDAQ:VERO) last posted its earnings results on Tuesday, August 13th. The company reported ($1.39) earnings per share (EPS) for the quarter. The company had revenue of $16.58 million during the quarter. On average, equities analysts forecast that Venus Concept will post -6.37 earnings per share for the current year.

Institutional Trading of Venus Concept

A hedge fund recently raised its stake in Venus Concept stock. Masters Capital Management LLC grew its position in shares of Venus Concept Inc. (NASDAQ:VERO) by 100.0% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 666,702 shares of the company’s stock after acquiring an additional 333,366 shares during the quarter. Masters Capital Management LLC owned 10.49% of Venus Concept worth $522,000 at the end of the most recent reporting period. 87.41% of the stock is owned by institutional investors.

About Venus Concept

Venus Concept Inc, a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; Venus Versa Pro; and Venus Viva and Venus Viva MD, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin.